References

• Zubieta, J., Greenwald, M. K., Lombardi, U., Woods, J. H., Kilbourn, M. R., Jewett, D. M., Koeppe, R. A., Schuster, C. R., & Johanson, C. E. (2000). Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 23(3), 326–334. https://doi.org/10.1016/S0893-133X(00)00110-X
• Lee, J. D., Nunes, E. V., Jr., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., King, J., Lindblad, R., Liu, D., Matthews, A. G., May, J., Peavy, K. M., Ross, S., Salazar, D., Schkolnik, P., ... Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. The Lancet, 391(10118), 309–318. https://doi.org/10.1016/S0140-6736(17)32812-X
• Tanum, L., Solli, K. K., Latif, Z., Benth, J. Š., Opheim, A., Sharma-Haase, K., ... & Clausen, T. (2017). Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial. JAMA Psychiatry, 74(12), 1197–1205. https://doi.org/10.1001/jamapsychiatry.2017.3206
• Burns, J. A., Kroll, D. S., Feldman, D. E., Kure Liu, C., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G.-J. (2019). Molecular imaging of opioid and dopamine systems: Insights into the pharmacogenetics of opioid use disorders. Frontiers in Psychiatry, 10, 626. https://doi.org/10.3389/fpsyt.2019.00626